COVID-19 Multiple Myeloma Patient Study
What is the COVID-19 / Multiple Myeloma Patient Study?
Myeloma patients have a superpower. We can join together to quickly answer critical questions to help us get through the COVID-19 crisis and come out stronger, healthier and more knowledgeable in the process.
Patients have the power to answer questions such as:
Is my myeloma treatment making my risk for COVID-19 worse?
Is my myeloma therapy protecting me against COVID-19?
Did my myeloma treatment change because of COVID-19?
If I skip or delay treatment, how will that impact my outcomes?
How is COVID-19 affecting me financially? Emotionally?
Is my blood type or ethnicity increasing my risk for COVID-19?
And answers to over 40 more questions.
Each study participant will also receive a free rapid COVID-19 antibody test. This is a fingerprick blood test that identifies if you have developed coronavirus antibodies.
This test should be administered by a healthcare professional, so take it with you to your next clinic appointment or perform the test during your next telemedicine visit. This rapid test was used in a 3200 patient Stanford study and has been verified in a CLIA approved lab.
Who Can Join the COVID-19 / Multiple Myeloma Study?
All multiple myeloma patients and precursor condition patients (MGUS and SMM) are invited to join. You can join the study if you are COVID-19 positive or negative. Our goal is to include 1000 patients in the study.
How Do I Join the Study?
1. Visit www.healthtree.org
2. Create a HealthTree Profile
3. Click Accelerate Myeloma Research
4. Click Multiple Myeloma and COVID-19/Join Study
HealthTree is a tool that helps you navigate your myeloma AND enables this type of rapid research to develop new, faster hypotheses. HealthTree was created by the Myeloma Crowd for myeloma patients by myeloma patients.
Multiple Myeloma Researcher Review
This study has been jointly created and reviewed by the following multiple myeloma researchers:
Rafael Fonseca, MD, Mayo Clinic
Faith Davies, MD, NYU Langone
Ivan Borrello, MD, Johns Hopkins
Ola Landgren, MD, PhD, Memorial Sloan Kettering Cancer Center
Caitlin Costello, MD, UCSD
Mike Thompson, MD, PhD, Aurora Healthcare
Why Donate to the Myeloma Crowd Research Initiative (MCRI) COVID-19 Study?
The Myeloma Crowd Research Initiative is a crowdsourcing method of funding important myeloma research. The first Myeloma Crowd Research Initiative (MCRI) successfully raised $500,000 for two immunotherapy research projects for high-risk myeloma (CAR T and T cell treatments). The second MCRI campaign raised $250,000 for personalized myeloma therapies.
Now we invite you to donate to this important project that will provide new insights in the relationship between COVID-19 and myeloma. Help us identify the best possible protective therapies against COVID-19 for myeloma patients by donating to the MCRI today.